Theravance Biopharma enters merger agreement with Zymeworks.
Theravance Biopharma signed an agreement and plan of merger with Zymeworks Inc., aiming to combine their biopharmaceutical operations. This M&A transaction signals a strategic consolidation in the therapeutic antibody sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day